Nanjing Vazyme Biotech Co., Ltd (SHA:688105)
China
· Delayed Price · Currency is CNY 19.90
+0.19 (0.96%)
Apr 29, 2026, 3:00 PM CST
Nanjing Vazyme Biotech Revenue
Nanjing Vazyme Biotech had revenue of 320.65M CNY in the quarter ending March 31, 2026, with 12.52% growth. This brings the company's revenue in the last twelve months to 1.41B, up 3.84% year-over-year. In the year 2025, Nanjing Vazyme Biotech had annual revenue of 1.38B, down -0.00%.
Revenue (ttm)
1.41B
Revenue Growth
+3.84%
P/S Ratio
5.60
Revenue / Employee
493.04K
Employees
2,754
Market Cap
7.91B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Acrobiosystems | 887.21M |
| Jiangsu Aidea Pharmaceutical Group | 719.17M |
| Chengdu Kanghua Biological Products | 1.20B |
| Suzhou Fengbei Biotech Stock | 3.17B |
| Daan Gene | 765.48M |
| GemPharmatech | 830.61M |
| Anhui Huaheng Biotechnology | 2.95B |
| Zhejiang Ausun Pharmaceutical | 751.12M |